HEALTHDAILY MAIL
Cancer vaccine slashes risk of deadly skin cancer returning by nearly half in major trial
A cancer vaccine reduced the risk of deadly skin cancer returning by nearly half in a major clinical trial. The trial demonstrated the vaccine's effectiveness in preventing recurrence of the disease.
Related Signal
Adjacent reporting
- A cancer vaccine made just for you. mRNA is back and it's fighting melanoma
- A cancer vaccine made just for you. mRNA is back and it's fighting melanoma
- A personalized vaccine for melanoma cut the risk of cancer returning after five years
- Pancreatic cancer mRNA vaccine shows lasting results in an early trial
- Delivering an immune therapy into tumours instead of intravenously reduces adverse effects
- Drugs that boost immunity are making lung cancer less deadly